Datopotamab Deruxtecan
Brand names: Datroway · Active ingredient: Datopotamab Deruxtecan
In short: DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerate
What is Datopotamab Deruxtecan used for?
DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy .
DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Datopotamab Deruxtecan dosage
Select patients with locally advanced or metastatic NSCLC for treatment with DATROWAY based on the presence of epidermal growth factor receptor (EGFR) mutations in tumor or plasma specimens . Testing may be performed at any time from initial diagnosis and does not need to be repeated once EGFR mutation status has been established.
The recommended dosage of DATROWAY is 6 mg/kg (up to a maximum of 540 mg for patients ≥90 kg) administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses.
Conduct an ophthalmic exam including visual acuity testing, slit lamp examination (with fluorescein staining), intraocular pressure, and fundoscopy at initiation of DATROWAY, at end of treatment, and as clinically indicated. While on treatment, conduct visual acuity testing and slit lamp examination every 3 cycles.
Administer DATROWAY with the premedication and concomitant medications described in Table 1.
Monitor patients for infusion-related reactions in a setting where cardiopulmonary resuscitation medication and equipment are available. Monitor patients for at least 1 hour for the first 2 cycles of DATROWAY infusions. If there are no infusion-related reactions observed, monitor patients for at least 30 minutes for all subsequent cycles of infusions.
PremedicationWith or without systemic corticosteroid | Examples (or equivalent) | Timing of Treatment/Duration
Eye drops
| Preservative-free lubricant eye drops | Administer at least four times daily and as needed
Mouthwash
| Steroid-containing mouthwash (dexamethasone oral solution 0.1 mg/mL) | Administer four times daily and as needed
Antihistamine
| Diphenhydramine (25 to 50 mg) administered intravenously or orally | Administer 30-60 minutes prior to each infusion
Antipyretic
| Acetaminophen (650 to 1,000 mg) administered intravenously or orally | Administer 30-60 minutes prior to each infusion
Antiemetics
| 5-HT3 serotonin receptor antagonist or appropriate alternatives intravenously or oral | Prior to each infusion and thereafter as needed
Dosage Modifications for Adverse Reactions
The recommended dose reduction levels for adverse reactions are described in Table 2.
Dose Reductions | Recommended Dose
First | 4 mg/kg (up to a maximum of 360 mg for patients ≥90 kg)
Second | 3 mg/kg (up to a maximum of 270 mg for patients ≥90 kg)
Third | Permanently discontinue
Do not re-escalate the DATROWAY dose after a dose reduction. Permanently discontinue DATROWAY in patients who are unable to tolerate 3 mg/kg intravenously once every 3 weeks. …
How to take Datopotamab Deruxtecan — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Interstitial Lung Disease/Pneumonitis
Inform patients of the risks of severe or fatal ILD. Advise patients to contact their healthcare provider immediately for any of the following: cough, shortness of breath, fever, or other new or worsening respiratory symptoms .
Ocular Adverse Reactions
Inform patients about the need for eye exams at initiation and during treatment with DATROWAY .
Advise patients to contact their healthcare provider if they experience any eye symptoms .
Advise patients to use preservative-free lubricating eye drops at least four times daily and as needed and to avoid use of contact lenses during treatment with DATROWAY .
Stomatitis
Inform patients of the risk of stomatitis. Advise patients to contact their healthcare provider if they experience any symptoms.
Inform patients to use a steroid-containing mouthwash for prophylaxis and treatment of stomatitis.
Instruct patients to hold ice chips or ice water in their mouth throughout the infusion of DATROWAY .
Embryo-Fetal Toxicity
Inform female patients of the potential risk to a fetus. …
Warnings & precautions
Do not take this medicine if: None.
DATROWAY can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.
Locally Advanced or Metastatic NSCLC
In the pooled safety population of 484 patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01 , ILD/pneumonitis occurred in 7% of patients treated with DATROWAY, including 0.6% of patients with Grade 3 and 0.4% with Grade 4. There were 8 (1.7%) fatal cases. The median time to first onset for ILD was 1.4 months (range: 0.2 months to 9 months). Eleven patients (2.3%) had DATROWAY withheld and 20 patients (4.1%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 79% (26/33) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 45% of patients.
Unresectable or Metastatic Breast Cancer
In the pooled safety population of 841 patients with breast cancer from TROPION-Breast01, TROPION-Breast02, TROPION-PanTumor01 and TROPION-PanTumor02 , ILD/pneumonitis occurred in 3.0% of patients treated with DATROWAY, including 0.4% of patients with Grade 3. There were two fatal cases (0.2%). The median time to first onset for ILD was 5.3 months (range: 1.1 months to 19.3 months) and with a median duration of 1.2 months (range: 0.3 to 5.2). Eight patients (1.0%) had DATROWAY withheld and 10 patients (1.2%) permanently discontinued DATROWAY due to ILD/pneumonitis. Systemic corticosteroids were required in 64% (16/25) of patients with ILD/pneumonitis. ILD/pneumonitis resolved in 40% of patients.
Patients were excluded from clinical studies for a history of ILD/pneumonitis requiring treatment with steroids or for ongoing ILD/pneumonitis.
Monitor patients for new or worsening respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever) during treatment with DATROWAY. …
Datopotamab Deruxtecan side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Interstitial Lung Disease/Pneumonitis
Ocular Adverse Reactions
Stomatitis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in WARNINGS AND PRECAUTIONS reflects exposure to DATROWAY in 1365 patients as a single agent at 6 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. This included 137 patients with NSCLC in TROPION-Lung05 , 297 patients with NSCLC in TROPION-Lung01 , 360 patients with HR-positive, HER2-negative breast cancer in TROPION-Breast01 , 319 patients with TNBC in TROPION-Breast02 , 50 patients with NSCLC and 83 patients with breast cancer in TROPION-PanTumor01 (NCT03401385), and 40 patients with NSCLC and 79 patients with breast cancer in TROPION-PanTumor02 (NCT05460273). Among the 1365 patients who received DATROWAY, 48% were exposed for greater than 6 months and 22% were exposed for greater than one year. In this pooled safety population, the most common (≥20%) adverse reactions were stomatitis (63%), nausea (51%), fatigue (42%), alopecia (38%), constipation (30%), vomiting (23%), decreased appetite (22%), and rash (20%). …
About this medicine
Datopotamab deruxtecan-dlnk is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Datopotamab deruxtecan-dlnk is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-Trop-2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase I inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.
The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Approximately 4 molecules of deruxtecan are attached to each antibody molecule. Datopotamab deruxtecan-dlnk has the following structure:
DATROWAY (datopotamab deruxtecan-dlnk) for injection is a sterile, white to yellowish white, preservative-free lyophilized powder in single-dose vials. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2950227c-6230-4ca4-a135-46e44d9424a0. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate